Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population.

Berman, Julia; Furer, Victoria; Berman, Mark; Isakov, Ofer; Zisman, Devy; Haddad, Amir; Elkayam, Ori

Berman, Julia; Furer, Victoria; Berman, Mark; Isakov, Ofer; Zisman, Devy; Haddad, Amir; Elkayam, Ori.

Afiliação

Berman J; Department of Medicine 'T', Sourasky Medical Center, Tel Aviv, Israel.
Furer V; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Berman M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Isakov O; Department of Rheumatology, Sourasky Medical Center, Tel Aviv, Israel.
Zisman D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Haddad A; Department of Rheumatology, Sourasky Medical Center, Tel Aviv, Israel.
Elkayam O; Department of Medicine 'T', Sourasky Medical Center, Tel Aviv, Israel.

Biologics ; 15: 463-470, 2021.

Article em En | MEDLINE | ID: mdl-34819720

Palavras-chave

antibodies; arthritis; duration of therapy; humanized; ixekizumab; monoclonal; psoriasis; psoriatic; secukinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Idioma: En Revista: Biologics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google